Centessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Sold by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC cut its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 64.1% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 26,073 shares of the company’s stock after selling 46,536 shares during the period. Cubist Systematic Strategies LLC’s holdings in Centessa Pharmaceuticals were worth $235,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD grew its holdings in shares of Centessa Pharmaceuticals by 16.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company’s stock worth $33,427,000 after buying an additional 418,615 shares in the last quarter. Nantahala Capital Management LLC purchased a new stake in shares of Centessa Pharmaceuticals in the second quarter valued at about $4,064,000. Driehaus Capital Management LLC grew its holdings in shares of Centessa Pharmaceuticals by 89.5% in the second quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock valued at $18,891,000 after purchasing an additional 987,997 shares during the period. First Light Asset Management LLC grew its holdings in shares of Centessa Pharmaceuticals by 59.2% in the second quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock valued at $43,168,000 after purchasing an additional 1,778,515 shares during the period. Finally, Farallon Capital Management LLC grew its holdings in shares of Centessa Pharmaceuticals by 438.0% in the second quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock valued at $18,024,000 after purchasing an additional 1,625,000 shares during the period. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Up 4.2 %

Shares of CNTA opened at $16.66 on Tuesday. The stock has a market capitalization of $1.67 billion, a PE ratio of -11.73 and a beta of 1.46. Centessa Pharmaceuticals plc has a 1 year low of $5.58 and a 1 year high of $17.59. The company has a debt-to-equity ratio of 0.27, a quick ratio of 13.29 and a current ratio of 13.29. The company’s 50-day simple moving average is $14.28 and its 200-day simple moving average is $11.21.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Analysts forecast that Centessa Pharmaceuticals plc will post -1.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on CNTA. Oppenheimer reissued an “outperform” rating and issued a $14.00 price objective on shares of Centessa Pharmaceuticals in a report on Wednesday, August 14th. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $11.00 to $26.00 in a report on Thursday, September 19th. Jefferies Financial Group increased their target price on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Guggenheim increased their target price on shares of Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Finally, BMO Capital Markets increased their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research note on Monday, September 16th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $25.17.

Insider Activity at Centessa Pharmaceuticals

In related news, CEO Saurabh Saha sold 4,169 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total value of $51,362.08. Following the sale, the chief executive officer now owns 827,755 shares of the company’s stock, valued at $10,197,941.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $15.00, for a total transaction of $375,000.00. Following the sale, the insider now owns 223,369 shares of the company’s stock, valued at approximately $3,350,535. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Saurabh Saha sold 4,169 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $12.32, for a total transaction of $51,362.08. Following the sale, the chief executive officer now directly owns 827,755 shares in the company, valued at approximately $10,197,941.60. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 288,492 shares of company stock valued at $4,641,902 over the last 90 days. 11.59% of the stock is owned by corporate insiders.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.